Jacobio Pharmaceuticals (HKG:1167) said its cash runway extends at least four years, supported by about 2.10 billion yuan in cash and bank balances, capital-protected structured deposits, and available bank credit facilities, according to a Tuesday Hong Kong bourse filing.
The drug company said it has repurchased 747,800 shares for about HK$34.2 million as of May 18.
Jacobio also received a $100 million upfront payment from AstraZeneca under a strategic collaboration agreement, along with 8.6 million yuan in sales royalty payments from Allist for the June-to-December 2025 period, the filing said.